The Cancer Biotherapy Research Group [CBRG], formerly the National Biotherapy Study Group [NBSG]: a 10-Year Perspective
- 1 August 1997
- journal article
- review article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 12 (4) , 229-242
- https://doi.org/10.1089/cbr.1997.12.229
Abstract
The Cancer Biotherapy Research Group [CBRG], formerly known as the National Biotherapy Study Group [NBSG], celebrated its 10th anniversary in 1997. CBRG is a not-for-profit cancer clinical trials group of community oncologists whose activities for the most part have been funded by their associated community hospitals. From its inception the Group has focused on clinical investigations of biological agents in the treatment of patients with advanced cancer. This article reviews the history of the Group, its structure, accomplishments, and its current objectives and challenges.Keywords
This publication has 22 references indexed in Scilit:
- SURVIVAL OF PATIENTS WITH METASTATIC CANCER FOR MORE THAN THREE YEARS AFTER STARTING CONTINUOUS INFUSION IL-2 THERAPY IN TRIALS OF THE NATIONAL BIOTHERAPY STUDY GROUP (NBSG)Journal of Immunotherapy, 1995
- Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experienceCancer, 1993
- Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.Journal of Clinical Oncology, 1991
- Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trialCancer, 1991
- Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated With Dacarbazine Therapy in Melanoma: A National Biotherapy Study Group TrialJNCI Journal of the National Cancer Institute, 1990
- Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapyJournal of Immunological Methods, 1990
- Monoclonal Antibodies for Treating CancerAnnals of Internal Medicine, 1989
- An improved method for the generation of human lymphokine activated killer cellsJournal of Immunological Methods, 1987
- On Lymphokines, Cytokines, and BreakthroughsPublished by American Medical Association (AMA) ,1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985